In most patients with type 2 diabetes mellitus (T2DM) and progressive betacell insufficiency, insulin therapy is required to achieve sufficient glycemic control. However, insulin therapy may lead to weight gain and increasing risk of hypoglycemia. Glucagon-like peptide-1 receptor agonists are being used as addon therapy to insulin with favorable metabolic effects. Nonetheless, to date only few studies exist reporting on the combination of liraglutide and insulin with a short follow-up period. The aim of this study was to evaluate the efficacy and safety of liraglutide as add-on to insulin in patients with T2DM over a time period of up to 24-28 months.
INTRODUCTION
Lifestyle modification and oral antidiabetic drugs are first line treatment measures in patients with type 2 diabetes mellitus (T2DM).
Over time, progressive beta cell dysfunction results in deteriorating glycemic control requiring insulin therapy. However, insulin is often associated with weight gain and increased risk of hypoglycemia [1] . Together with the need for (multiple) injections, insulin therapy frequently meets reluctance in both patients and physicians, and initiation of therapy is often delayed [2] . Several trials showed that Glucagon-like peptide-1 (GLP-1) receptor agonists as monotherapy or in combination with one or more oral antidiabetic agent have beneficial metabolic effects leading to improved glycemic control with a low risk of hypoglycemia, and weight loss [3] . They are now recommended as one of several two-drug combination therapies, if metformin monotherapy does not achieve/maintain the defined glycated hemoglobin (HbA1c) target over 3 months [4] .
Several reports demonstrated favorable effects of a combination therapy of a GLP-1 receptor agonist with insulin [5]. However, only few studies included the use of liraglutide [6-10], and follow-up time was short. Despite these limited data, liraglutide is widely used (offlabel) as add-on therapy in patients on various insulin regimens and oral antidiabetic drugs. In 2013, liraglutide was officially approved for use in combination with basal insulin in Europe (and the US). The aim of this observational study was to retrospectively assess the efficacy and safety of liraglutide as add-on therapy to insulin in a daily clinical practice setting for a duration up to 24-28 months.
METHODS
Eligible participants were adults (18-80 years) with T2DM, BMI C 28 kg/m 2 and HbA1c values of 6.5-10% treated with metformin ± another oral antidiabetic drug and insulin. Exclusion Starting dose of liraglutide was 0.6 mg once daily, with an increase to 1.2 mg after 2 weeks. During the treatment period, no additional antidiabetic drug was initiated. Oral drugs and insulin dosage were individually reduced by the attending physician according to current glucose control. As the outpatient clinic is part of a teaching hospital, all physicians followed the same treatment strategies according to the guidelines of the Swiss Society of Endocrinology and Diabetes [11] . Hypoglycemic events were assessed by patient interview and patients' blood glucose meter readings were imported into the DIABASS Ò Pro 7.7% (IQR 7.0-8.6) at baseline to 6.8% (IQR 6.5-7.7, p = 0.001) at 3 months and 6.9%, (IQR 6.3-7.6, p = 0.0001) at 6 months, but re-increased at 12-16 months (median 7.2%, IQR 6.7-7.9, p = 0.32) and 24-28 months (median 7.5%, IQR 7.1-8.2, p = 1.0). HbA1c prior to intervention was lower (median 7.3%, IQR 7.1-7.9) than at baseline. Weight and BMI decreased significantly from 99.8 kg and 33.5 kg/m 2 (IQR 81-110 and 29.4-37.6) respectively at baseline to 97.7 kg and 31.9 kg/ m 2 (IQR 81.2-108.2 and 29.4-36), (p = 0.023 and 0.027) at 3 months. However weight and BMI increased again after 6 months (median 97.5 kg and 31.5 kg/m 2 , IQR 84.5.5-111.5, p = 0.16 and 29.4-35.1, p = 0.15), at 12-16 months (100.5 kg and 34.1 kg/m 2 , IQR 100.5-109.5, p = 0.17 and 30.7-36.7, p = 0.16) and at 24-28 months (106.4 kg and 36.4 kg/m 2 , IQR 96.9-118, p = 1.0 and 30.9-38.4, p = 1.0).
Insulin dosage did not change significantly over time (Fig. 1) . However, during follow-up, three patients (10.3%) were able to completely stop insulin therapy, and two patients (6.9%) could simplify their multiple daily insulin injection regimens to basal insulin at bedtime only. In contrast to other studies with GLP-1 receptor agonists and insulin [17] , there was no statistically significant reduction in daily insulin dose in the present study. However, a remarkable proportion of the patients either completely ceased insulin or at least were able to omit prandial insulin injections. Moreover, in many of the patients, oral antidiabetic drugs (beside metformin) could be stopped, which is especially beneficial for patients with sulfonylureas bearing an increased risk of hypoglycemia.
In accordance with earlier reports, liraglutide was well tolerated. Remarkably, no events of severe hypoglycemia were observed in the present cohort. The dropout rate of 15.6% due to side effects was comparable to other reports [18, 19] .
Limitations of this study are the small patient number and potentially heterogeneous patient characteristics, including patients with long-standing diabetes as well as the 
